154 related articles for article (PubMed ID: 35156573)
1. In Search of HIV Entry Inhibitors Using Molecular Docking, ADME, and Toxicity Studies of Some Thiazolidinone-Pyrazine Derivatives Against CXCR4 Co-receptor.
Patil SM; Asgaonkar KD; Bakhle B; Abhang K; Khater A; Singh M; Chitre TS
Curr HIV Res; 2022 Aug; 20(2):152-162. PubMed ID: 35156573
[TBL] [Abstract][Full Text] [Related]
2. Comparative Docking Studies: A Drug Design Tool for Some Pyrazine- Thiazolidinone Based Derivatives for Anti-HIV Activity.
Asgaonkar KD; Patil SM; Chitre TS; Ghegade VN; Jadhav SR; Sande SS; Kulkarni AS
Curr Comput Aided Drug Des; 2019; 15(3):252-258. PubMed ID: 30569873
[TBL] [Abstract][Full Text] [Related]
3. Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor.
Pettersson S; Pérez-Nueno VI; Mena MP; Clotet B; Esté JA; Borrell JI; Teixidó J
ChemMedChem; 2010 Aug; 5(8):1272-81. PubMed ID: 20533501
[TBL] [Abstract][Full Text] [Related]
4. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
[TBL] [Abstract][Full Text] [Related]
6. Designing and
Patil SM; Shashikant B
Curr Drug Discov Technol; 2023; 20(6):47-59. PubMed ID: 37291789
[TBL] [Abstract][Full Text] [Related]
7. Interactions of selected cardiovascular active natural compounds with CXCR4 and CXCR7 receptors: a molecular docking, molecular dynamics, and pharmacokinetic/toxicity prediction study.
Murad HAS; Alqurashi TMA; Hussien MA
BMC Complement Med Ther; 2022 Feb; 22(1):35. PubMed ID: 35120520
[TBL] [Abstract][Full Text] [Related]
8. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
9. Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Das D; Maeda K; Hayashi Y; Gavande N; Desai DV; Chang SB; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 Apr; 59(4):1895-904. PubMed ID: 25583709
[TBL] [Abstract][Full Text] [Related]
10. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
[TBL] [Abstract][Full Text] [Related]
11. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
12. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
13. Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.
Mirza MU; Saadabadi A; Vanmeert M; Salo-Ahen OMH; Abdullah I; Claes S; De Jonghe S; Schols D; Ahmad S; Froeyen M
Eur J Pharm Sci; 2020 Dec; 155():105537. PubMed ID: 32890663
[TBL] [Abstract][Full Text] [Related]
14. The HIV entry inhibitors revisited.
Leonard JT; Roy K
Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075
[TBL] [Abstract][Full Text] [Related]
15. One-Pot Synthesis of Novel Hydrazono-1,3-Thıazolıdın-4-One Derivatives as Anti-HIV and Anti-Tubercular Agents: Synthesıs, Bıologıcal Evaluatıon, Molecular Modelling and Admet Studıes.
Pasha MA; Mondal S; Panigrahi N; Shetye G; Ma R; Franzblau SG; Zheng YT; Murugesan S
Curr HIV Res; 2022; 20(3):255-271. PubMed ID: 35549861
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking.
Pérez-Nueno VI; Ritchie DW; Rabal O; Pascual R; Borrell JI; Teixidó J
J Chem Inf Model; 2008 Mar; 48(3):509-33. PubMed ID: 18298095
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 entry inhibitors: an overview.
Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
[TBL] [Abstract][Full Text] [Related]
20. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
Zhang C; Du C; Feng Z; Zhu J; Li Y
Chem Biol Drug Des; 2015 Feb; 85(2):119-36. PubMed ID: 24923360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
